Key result
Bone marrow cell therapy shows safety and efficacy for MI by attenuating adverse remodeling.
Answers are grounded in this paper and cite their sources.
Cell therapy has tremendous potential for the damaged heart, which has limited self-renewing capability. Bone marrow (BM) cells are attractive for cell therapy, as they contain diverse stem and progenitor cell populations that can give rise to various cell types, including cardiomyocytes, endothelial cells, and smooth muscle cells. Studies have shown BM cells to be safe and efficacious in the treatment of myocardial infarction. Possible therapeutic mechanisms mediated by both host and transplanted cells include cardiomyogenesis, neovascularization, and attenuation of adverse remodeling. In this review, different stem and progenitor cells in the bone marrow and their application in cell therapy are reviewed, and evidence for their therapeutic mechanisms is discussed.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2009) conducted a review in Myocardial infarction. Bone marrow cell therapy was evaluated. Bone marrow cell therapy is reviewed as a safe and efficacious treatment for myocardial infarction via cardiomyogenesis, neovascularization, and attenuation of adverse remodeling.
Synapse has enriched 10 related papers. Consider them for comparative context: